ClinicalTrials.gg
CompletedNCT00380588Updated Nov 20, 2009Results posted

Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer

A Phase 2 interventional study of gemcitabine and cisplatin in Biliary Tract Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing gemcitabine in Biliary Tract Neoplasms — 9 open to participants now, 13 under way, 2 of them phase 3. Gemcitabine · Biliary Tract Neoplasms.

Enrollment
11th of 49
84 · median 44
Started
2006
with 1 other
Phase 2
28 of 49
4 open now
Registered
4th of 49
by date

Among the 49 studies testing gemcitabine in Biliary Tract Neoplasms, this one is the 11th largest by enrollment, is one of 2 that started in 2006, is one of 28 in phase 2, and was the 4th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

9 of the 49 studies testing gemcitabine in Biliary Tract Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Biliary Tract Neoplasms studies recruiting now, 81 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gemcitabine in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

To investigate efficacy and safety of gemcitabine combined with cisplatin and of gemcitabine alone by comparison in patients with advanced biliary tract cancer

03

Conditions studied

  • Biliary Tract Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of biliary tract cancer
  • must be at least one lesion
  • Chemotherapy-naïve
  • (ECOG) performance status 0 or 1
  • Estimated no less than 3 months

Exclusion criteria

Exclusion Criteria:

  • radiological or clinical evidence of pulmonary fibrosis or interstitial pneumonia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Gemcitabine + Cisplatin

    Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal. Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.

    Drug: gemcitabine · Drug: cisplatin

  • Experimental
    Gemcitabine

    Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.

    Drug: gemcitabine

Interventions

  • 1000 milligrams per square meter (mg/m2), intravenous (IV)

    Also known as: LY188011, Gemzar

  • 25 milligrams per square meter (mg/m2), intravenous (IV)

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Alive at 1 Year (1-Year Survival Rate)

    Percentage of patients alive at 1 year.

    Time frame: 1 year

Secondary outcomes

  1. Tumor Response

    Response Evaluation Criteria In Solid Tumors - define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Complete response (CR) = disappearance of all target lesions; Partial Response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (up to 2 years)

  2. Progression Free Survival

    The period from study entry until disease progression, death or date of last contact.

    Time frame: baseline to measured progressive disease (up to 2 years)

Other outcomes

  1. Survival Time

    Data of patients lost to follow-up were censored at the last date of confirmation of their survival.

    Time frame: baseline to date of death due to any cause (up to 2 years)

07

Results

Posted Nov 19, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine + CisplatinGemcitabine
Started4242
Received at least one dose of study drug4142
Completed32
Not completed3940
Withdrew: Unequivocal disease progression2534
Withdrew: Next cycle not started40
Withdrew: Adverse event73
Withdrew: Withdrawal by subject13
Withdrew: Physician decision20

Outcome measures

PrimaryPercentage of Patients Alive at 1 Year (1-Year Survival Rate)

Percentage of patients alive at 1 year.

Time frame:
1 year
Reported as:
Number · percentage of participants
Percentage of Patients Alive at 1 Year (1-Year Survival Rate)
percentage of participantsGemcitabine + CisplatinGemcitabine
Percentage of Patients Alive at 1 Year (1-Year Survival Rate)3931
SecondaryTumor Response

Response Evaluation Criteria In Solid Tumors - define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Complete response (CR) = disappearance of all target lesions; Partial Response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (up to 2 years)
Reported as:
Number · participants
Tumor Response
participantsGemcitabine + CisplatinGemcitabine
Complete Response00
Partial Response85
Stable Disease2016
Progressive Disease917
Not Evaluable44
Statistical analysis
  • Gemcitabine + Cisplatin vs Gemcitabine · Fisher Exact · p = 0.380 (P-value for response (Complete Response + Partial Response).)
SecondaryProgression Free Survival

The period from study entry until disease progression, death or date of last contact.

Time frame:
baseline to measured progressive disease (up to 2 years)
Reported as:
Median · months
Progression Free Survival
monthsGemcitabine + CisplatinGemcitabine
Progression Free Survival5.8 (4.1 to 8.2)3.7 (2.1 to 5.3)
Statistical analysis
  • Gemcitabine + Cisplatin vs Gemcitabine · Log Rank · p = 0.074
Other pre-specifiedSurvival Time

Data of patients lost to follow-up were censored at the last date of confirmation of their survival.

Time frame:
baseline to date of death due to any cause (up to 2 years)
Reported as:
Median · months
Survival Time
monthsGemcitabine + CisplatinGemcitabine
Survival Time11.2 (9.1 to 12.5)7.7 (6.1 to 11.0)
Statistical analysis
  • Gemcitabine + Cisplatin vs Gemcitabine · Log Rank · p = 0.136

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine + Cisplatin—9/41 (22%)41/41 (100%)
Gemcitabine—17/42 (40.5%)42/42 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventGemcitabine + CisplatinGemcitabine
CholangitisHepatobiliary disorders4/418/42
Jaundice cholestaticHepatobiliary disorders2/414/42
Liver abscessInfections and infestations2/410/42
AnaemiaBlood and lymphatic system disorders1/410/42
Duodenal stenosisGastrointestinal disorders1/410/42
HaemobiliaHepatobiliary disorders1/410/42
Platelet count decreasedInvestigations1/410/42
Cerebral infarctionNervous system disorders1/410/42
Renal failure acuteRenal and urinary disorders1/410/42
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/411/42
Most frequent other events
Showing 10 of 69
Most frequent other events
EventGemcitabine + CisplatinGemcitabine
White blood cell count decreasedInvestigations36/4129/42
Haemoglobin decreasedInvestigations35/4136/42
Neutrophil count decreasedInvestigations34/4129/42
Platelet count decreasedInvestigations33/4132/42
AnorexiaMetabolism and nutrition disorders33/4126/42
Red blood cell count decreasedInvestigations31/4133/42
NauseaGastrointestinal disorders28/4118/42
PyrexiaGeneral disorders18/4125/42
FatigueGeneral disorders24/4121/42
Haematocrit decreasedInvestigations24/4123/42

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine + CisplatinGemcitabineTotal
Mean63.7 ± 10.167.0 ± 6.965.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine + CisplatinGemcitabineTotal
Female232144
Male182139
Region of Enrollment
Region of Enrollment(participants)Gemcitabine + CisplatinGemcitabineTotal
Japan414283
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Gemcitabine + CisplatinGemcitabineTotal
0 - Fully Active342862
1 - Ambulatory, Restricted Strenuous Activity71421
Primary Tumor
Primary Tumor(participants)Gemcitabine + CisplatinGemcitabineTotal
Extrahepatic Bile Duct81119
Intrahepatic Bile Duct141428
Gallbladder151732
Papilla404
Tumor Histological Type
Tumor Histological Type(participants)Gemcitabine + CisplatinGemcitabineTotal
Adenocarcinoma394180
Adenosquamous Cancer213
Body Surface Area
Body Surface Area(square meter (m^2))Gemcitabine + CisplatinGemcitabineTotal
Mean1.555 ± 0.1951.523 ± 0.1581.539 ± 0.177
Height
Height(centimeters (cm))Gemcitabine + CisplatinGemcitabineTotal
Mean159.80 ± 8.75156.67 ± 8.62158.21 ± 8.77

1 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 466-8560, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 277-8577, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 811-1395, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 060-8648, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 241-0815, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shizuoka, 411-8777, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 104-0045, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2006
First posted
Sep 26, 2006
Start
Sep 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 19, 2009
Last update
Nov 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00380588
First posted
Sep 26, 2006
Start date
Sep 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 19, 2009
Last update
Nov 20, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion